发现和临床前评估强效,选择性和性共价WRN抑制剂,具有改善的PK特性
Zhaobing Xu1,2, Qi Xiao1,2, Yong Liu1,2
1Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., No. 666 High Tech Avenue, East Lake High Tech Development Zone, Wuhan, Hubei 430075, China.
一种新的药物,化合物22,有效地抑制维纳综合征酶 (WRN),并在微卫星不稳定性高的癌症的临床前模型中显示出显著的抗瘤活性.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 沃纳综合征基酶 (WRN) 是微卫星不稳定性高 (MSI-H) 癌症中合成致死性的关键标.
- 向WRN为特定癌症类型提供了一个有前途的治疗策略.
研究的目的:
- 发现和描述一种新型的WRN.的全共价抑制剂.
- 优化抑制剂的类似药物的特性,并评估其在临床前癌症模型中的有效性.
主要方法:
- 基于结构的药物设计被用来识别VVD-214中的化合物22.
- 在实验室中使用MSI-H结肠直肠癌细胞系 (HCT116) 进行了抗增殖试验.
- 在HCT116异种移植小鼠模型中进行了临床前药理动力学研究和体内疗效评估.
主要成果:
- 化合物22对HCT116细胞表现出强大的抗扩散活性.
- 与其前身VVD-214.4相比,它表现出较好的血稳定性和药理动力学暴露.
- 在HCT116异种移植小鼠模型中观察到显著的,剂量依赖的抗瘤活性.
结论:
- 化合物22代表了一种新的,优化的全共性WRN抑制剂.
- 其有利的临床前资料支持其进一步发展为MSI-H癌症的潜在治疗剂.
更多相关视频
06:17Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
Published on: February 28, 2025
10:24NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
Published on: June 30, 2019
相关概念视频
Drug-Receptor Bonds
In...
Pharmacogenomics: Identification of New Drug Targets
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Enzyme Inhibition
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Cooperative Allosteric Transitions
